Catalent Expert to Discuss Ways to Mitigate the Effects of Brexit on Clinical Trial Supply at PCT Europe Conference

Share Article

Catalent Pharma Solutions, the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, today announced that Pete Young, Director of Quality at Catalent’s Bolton, U.K. clinical supply facility, will present at the upcoming Partnerships in Clinical Trials (PCT) conference at the CCIB Convention Centre Barcelona, Barcelona, Spain on Nov. 27 – 29, 2018.

Catalent Pharma Solutions, the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, today announced that Pete Young, Director of Quality at Catalent’s Bolton, U.K. clinical supply facility, will present at the upcoming Partnerships in Clinical Trials (PCT) conference at the CCIB Convention Centre Barcelona, Barcelona, Spain on Nov. 27 – 29, 2018.

In his presentation, “What Does Brexit Mitigation Look Like in Practice?” on Thursday, Nov. 29 at 10 a.m., Mr. Young will discuss the current negotiation status, the regulatory impact of a no deal, “hard Brexit” scenario and the activities required to help mitigate the impact of Brexit on clinical trial supply. Attendees will learn how to better assess their operational readiness and what potential actions they can take to effectively manage clinical supplies in a changing landscape, while maintaining supply chains for studies in the U.K., EU and beyond.

In his role, Mr. Young has overall responsibility for quality, as well as being an Investigational Medicinal Products Qualified Person. He has over 20 years’ experience in the pharmaceutical industry, with prior roles in laboratories, production support and quality systems, where he has led facility upgrades and system deployments. Mr. Young holds a bachelor’s degree in biomedical chemistry, with further education in environmental analytical science and industrial pharmaceutical studies.

To arrange a meeting with Mr. Young at the conference, contact Richard Kerns at NEPR - richard(at)nepr.eu

About Catalent
Catalent is the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products. With 85 years serving the industry, Catalent has proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring reliable clinical and commercial product supply. Catalent employs over 11,000 people, including over 1,800 scientists, at more than 30 facilities across five continents, and in fiscal 2018 generated approximately $2.5 billion in annual revenue. Catalent is headquartered in Somerset, New Jersey. For more information, visit http://www.catalent.com.

More products. Better treatments. Reliably supplied.™

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Chris Halling

Richard Kerns
Northern Exposure Public Relations
+44 161 728 5880
Email >
Visit website